Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS
| Status: | Archived |
|---|---|
| Conditions: | Pneumonia, Infectious Disease, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2009 |
| End Date: | March 2012 |
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Doses of 13vPnC Vaccine in HIV-Infected Subjects 18 Years of Age or Older Who Have Been Previously Immunized With 23vPS Vaccine
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent
pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 18 years of age or older
who have been previously immunized with at least one dose of 23-valent pneumococcal
polysaccharide vaccine (23vPS). All subjects will receive 3 doses of 13vPnC, with each study
vaccine dose given approximately 6 months apart.
We found this trial at
9
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Darien Pediatric Associates Our office is pleased and privileged to care for your children and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials